Retension Pharmaceuticals: director Michael J Berendt received 5,636 shares

What happened The Form 4 filed Oct 8, 2026 shows Michael J Berendt, a director, received a grant of 5,636 derivative securities (option award) at $0.00 per share, total $0.

Key details

• Transaction date and price: Oct 8, 2026; $0.00 per share.
• Shares owned after the transaction: the filing does not report shares owned after the transaction.
• Footnote F1: option award granted under the issuer's 2026 Equity Incentive Plan; 25 percent of the stock option vests on the first anniversary of the grant, with the remaining options vesting in 12 quarterly increments thereafter, subject to continued service.
• Filing date and timeliness: Form 4 filed on Oct 8, 2026 (period of report Oct 8, 2026).

Why it may matter

• This was an option award (derivative), not a market purchase or sale.
• The filing does not show why the insider traded or why the company acted.